Eplontersen trial fails to meet primary endpoint in transthyretin-mediated amyloid cardiomyopathy
The CARDIO-TTRansform trial investigating eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy did not meet its primary efficacy endpoint, according to results presented in a Hot Line session at ESC Congress 2026.
<p>The CARDIO-TTRansform trial investigating eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy did not meet its primary efficacy endpoint, according to results presented in a Hot Line session at ESC Congress 2026.</p>